Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable CSCC Published in NEJM
“Regeneron conducted the first pivotal trial of Libtayo in advanced cutaneous squamous cell carcinoma that was unlikely to be curable by surgery or radiation, and we are now studying the utility of Libtayo in earlier stages of this disease. In addition to our neoadjuvant trial, a global Phase 3 trial of Libtayo is ongoing in the adjuvant setting after surgery and radiation for patients at heightened risk for recurrence,” said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron. “In the neoadjuvant trial in stage II to IV cutaneous squamous cell carcinoma presented at ESMO and published in NEJM, Libtayo demonstrated greater than 60% response rates per both pathologic and imaging measures. Libtayo may therefore have expanded utility in earlier stages of cutaneous squamous cell carcinoma as a monotherapy to potentially help avoid surgery, and as part of a combination approach with surgery to facilitate function-preserving resections and minimize disfigurement.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo